View in EDS

The MIDORA trial: a phase II, randomised, double-blind, placebo-controlled, mechanistic insight and dosage optimisation study of the efficacy and safety of dazodalibep in patients with rheumatoid arthritis.

Saved in:
Bibliographic Details
Title: The MIDORA trial: a phase II, randomised, double-blind, placebo-controlled, mechanistic insight and dosage optimisation study of the efficacy and safety of dazodalibep in patients with rheumatoid arthritis.
Authors: Kivitz A; Department of Rheumatology, Altoona Center for Clinical Research, Altoona, Pennsylvania, USA., Wang L; Horizon Therapeutics plc, Rockville, Maryland, USA., Alevizos I; Horizon Therapeutics plc, Rockville, Maryland, USA., Gunsior M; Horizon Therapeutics plc, Rockville, Maryland, USA., Falloon J; Horizon Therapeutics plc, Rockville, Maryland, USA., Illei G; Horizon Therapeutics plc, Rockville, Maryland, USA.; IRD Biomedical Consulting, LLC, Rockville, Maryland, USA., St Clair EW; Division of Rheumatology and Immunology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA stcla003@mc.duke.edu.
Source: RMD open [RMD Open] 2023 Aug; Vol. 9 (3).
Publication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Journal Info: Publisher: BMJ Publishing Group Country of Publication: England NLM ID: 101662038 Publication Model: Print Cited Medium: Internet ISSN: 2056-5933 (Electronic) Linking ISSN: 20565933 NLM ISO Abbreviation: RMD Open Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 37541743
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: The MIDORA trial: a phase II, randomised, double-blind, placebo-controlled, mechanistic insight and dosage optimisation study of the efficacy and safety of dazodalibep in patients with rheumatoid arthritis.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Kivitz+A%22">Kivitz A</searchLink>; Department of Rheumatology, Altoona Center for Clinical Research, Altoona, Pennsylvania, USA.<br /><searchLink fieldCode="AU" term="%22Wang+L%22">Wang L</searchLink>; Horizon Therapeutics plc, Rockville, Maryland, USA.<br /><searchLink fieldCode="AU" term="%22Alevizos+I%22">Alevizos I</searchLink>; Horizon Therapeutics plc, Rockville, Maryland, USA.<br /><searchLink fieldCode="AU" term="%22Gunsior+M%22">Gunsior M</searchLink>; Horizon Therapeutics plc, Rockville, Maryland, USA.<br /><searchLink fieldCode="AU" term="%22Falloon+J%22">Falloon J</searchLink>; Horizon Therapeutics plc, Rockville, Maryland, USA.<br /><searchLink fieldCode="AU" term="%22Illei+G%22">Illei G</searchLink>; Horizon Therapeutics plc, Rockville, Maryland, USA.; IRD Biomedical Consulting, LLC, Rockville, Maryland, USA.<br /><searchLink fieldCode="AU" term="%22St+Clair+EW%22">St Clair EW</searchLink>; Division of Rheumatology and Immunology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA stcla003@mc.duke.edu.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101662038%22">RMD open</searchLink> [RMD Open] 2023 Aug; Vol. 9 (3).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22BMJ+Publishing+Group%22">BMJ Publishing Group </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101662038 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>2056-5933 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2220565933%22">20565933 </searchLink><i>NLM ISO Abbreviation: </i>RMD Open <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=37541743
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1136/rmdopen-2023-003317
    Languages:
      – Code: eng
        Text: English
    Titles:
      – TitleFull: The MIDORA trial: a phase II, randomised, double-blind, placebo-controlled, mechanistic insight and dosage optimisation study of the efficacy and safety of dazodalibep in patients with rheumatoid arthritis.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Kivitz A
      – PersonEntity:
          Name:
            NameFull: Wang L
      – PersonEntity:
          Name:
            NameFull: Alevizos I
      – PersonEntity:
          Name:
            NameFull: Gunsior M
      – PersonEntity:
          Name:
            NameFull: Falloon J
      – PersonEntity:
          Name:
            NameFull: Illei G
      – PersonEntity:
          Name:
            NameFull: St Clair EW
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 08
              Text: 2023 Aug
              Type: published
              Y: 2023
          Identifiers:
            – Type: issn-electronic
              Value: 2056-5933
          Numbering:
            – Type: volume
              Value: 9
            – Type: issue
              Value: 3
          Titles:
            – TitleFull: RMD open
              Type: main
ResultId 1